Travere Therapeutics, Inc. (TVTX) Stock Price & Analysis
Travere Therapeutics, Inc. (TVTX) rose 3.16% to USD 48.57 as of June 10, 2026 at 00:55 UTC, according to Nexqual real-time market data.
TVTX last closed at USD 47.08; the session ranged USD 46.74–49.21 on volume of 2,213,908 shares. Market capitalization is $4.52B, with a 52-week range of USD 13.88–49.21 (NGM). Source: Nexqual, June 10, 2026 at 00:55 UTC.
Key Statistics (as of June 10, 2026 at 00:55 UTC)
| Price | USD 48.57 |
|---|---|
| Change | ▲ 3.16% (up) |
| Previous Close | USD 47.08 |
| Open | USD 47.88 |
| Day Range | USD 46.74 – 49.21 |
| 52-Week Range | USD 13.88 – 49.21 |
| Volume | 2,213,908 shares |
| Market Cap | $4.52B |
| Exchange | NGM |
Technical Analysis (TVTX)
Nexqual's technical model rates TVTX "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 00:55 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 64.8 (neutral) |
| vs SMA50 | Above (USD 40.81) |
| MACD | 1.68 (positive) |
Analyst Ratings (TVTX)
Wall Street analysts rate TVTX "Strong Buy" based on 14 analysts, with a mean price target of USD 55.07 (range USD 43–67), per Nexqual as of June 10, 2026 at 00:55 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 55.07 |
| High Target | USD 67 |
| Low Target | USD 43 |
| Buy / Hold / Sell | 14 / 1 / 0 |
Earnings (TVTX)
| Next Earnings Date | 2026-05-04 |
|---|---|
| EPS Estimate | USD 0.36 |
| Revenue Estimate | $162.69M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.05 vs est -0.06 ▲ beat |
| 2025-12-31 | USD 0.37 vs est 0.37 ▼ miss |
| 2025-09-30 | USD 0.59 vs est -0.09 ▲ beat |
| 2025-06-30 | USD 0.13 vs est 0.04 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:55 UTC.
Financials & Fundamentals (TVTX)
| Total Revenue | $536.20M |
|---|---|
| Revenue Growth (YoY) | +55.60% |
| Gross Margin | +55.95% |
| Operating Margin | -29.02% |
| Profit Margin | -4.00% |
| ROE | -69.38% |
| Debt / Equity | 331.88 |
| Current Ratio | 3.13 |
| Total Cash | $264.68M |
| Total Debt | $327.66M |
| Free Cash Flow | $-51.17M |
Source: Nexqual, June 10, 2026 at 00:55 UTC.
Financial Health Score (TVTX)
Nexqual rates Travere Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 00:55 UTC.
| Growth | Strong — Revenue +110% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 56%, operating -29% |
| Balance Sheet | Weak — $265M cash vs $328M debt |
| Cash Flow | Weak — FCF negative: -$51M, burning cash |
| Efficiency | Critical — ROE -69%, ROA -6.5% |
Ownership (TVTX)
| Insider Ownership | +0.80% |
|---|---|
| Institutional Ownership | +114.02% |
| Shares Outstanding | 92.99M |
| Float | 86.99M |
| Short % of Float | +19.70% |
Source: Nexqual, June 10, 2026 at 00:55 UTC.
Leadership (TVTX)
Travere Therapeutics, Inc. is led by Eric M. Dube (age 52), President, CEO & Director, per Nexqual as of June 10, 2026 at 00:55 UTC.
| President, CEO & Director | Eric M. Dube (age 52) |
|---|---|
| Chief Financial Officer | Christopher Cline C.F.A. (age 40) |
| Vice President of Corporate Communications & Investor Relations | Nivi Nehra |
Major Backers & Investors (TVTX)
Notable institutional backers of Travere Therapeutics, Inc. include Janus Henderson Group PLC, FMR, LLC, Fidelity, according to Nexqual as of June 10, 2026 at 00:55 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Janus Henderson Group PLC | 12.28% |
| FMR, LLC | 11.79% |
| Fidelity | 5.6% |
| Armistice Capital, LLC | 5.27% |
| Perceptive Advisors Llc | 4.45% |
| Nomura Asset Management International Inc | 3.52% |
| JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 2.72% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.47% |
| Vanguard Group | 9.94% |
| State Street | 8.77% |
Source: Nexqual, June 10, 2026 at 00:55 UTC.
From Travere Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
- The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
- Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria.
- It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VRDN | Viridian Therapeutics, Inc. | USD 16.31 | ▲ 3.36% |
| MIRM | Mirum Pharmaceuticals, Inc. | USD 95.48 | ▲ 2.14% |
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 34.97 | ▲ 6.23% |
| ARQT | Arcutis Biotherapeutics, Inc. | USD 22.79 | ▲ 7.35% |
| KYMR | Kymera Therapeutics, Inc. | USD 76.91 | ▲ 3.75% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:55 UTC. This page is informational and not investment advice.